GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VO... (re than 2000 patients have been treated ...)

GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)

Date:10/5/2009

re than 2,000 patients have been treated to date in clinical trials.

Pazopanib is not yet approved in any country.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary "bench to bedside" approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Note to Editors:

VOTRIENT(TM) is the proposed registered trademark to be used in the United States and Europe.

    Enquiries:
    UK Media enquiries:                   Philip Thomson       (020) 8047 5502
                                          Stephen Rea          (020) 8047 5502
                                          Alexandra Harrison   (020) 8047 5502
                                          Gwenan White         (020) 8047 5502
                                          Claire Brough        (020) 8047 5502

    US Media enquiries:                   Nancy Pekarek        (919) 483 2839
                                          Mary Anne Rhyne      (919) 483 2839
                                          Kevin Colgan         (919) 483 2839
                                          Sarah Alspach        (919) 483 2839

    European Analyst/Investor enquiries:  David Maw
'/>"/>
SOURCE  GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved 
0

GOOD

Page: 1 2 3 
Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
4. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
5. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
6. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

Post Your Comments:

GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VO...(re than 2000 patients have been treated ...),Health